Theravance Has Returned 23.2% Since SmarTrend Recommendation (THRX)
Comtex SmarTrend(R) - Tue May 13, 10:08AM CDT
SmarTrend identified a Downtrend for Theravance (NASDAQ:THRX) on March 7th, 2014 at $34.65. In approximately 2 months, Theravance has returned 23.23% as of today's recent price of $26.60.
Technical Coverage on Biotech Stocks -- Research on Athersys, Lexicon Pharma, Biogen Idec, and Theravance
PR Newswire - Mon May 12, 11:30AM CDT
On Friday, May 09, 2014, the NASDAQ Composite ended at 4,071.87, up 0.50%, the Dow Jones Industrial Average finished the day 0.20% higher at 16,583.34, and the S&P 500 closed at 1,878.48, up 0.15%. The gains were broad based as six out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 668.35, up 0.58%, and the index has advanced 3.66% in the last one month. Investor-Edge has initiated coverage on the following equities: Athersys Inc. (NASDAQ: ATHX), Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX), Biogen Idec Inc. (NASDAQ: BIIB) and Theravance Inc. (NASDAQ: THRX). Free technical research on ATHX, LXRX, BIIB and THRX can be downloaded upon signing up at:
This Week in Biotech: Chelsea Therapeutics Finds a Buyer While Corcept Implodes
Sean Williams, The Motley Fool - Motley Fool - Sat May 10, 11:15AM CDT
With the SPDR S&P Biotech Index up 20% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
Got Dividend? This Biotech Just Initiated a Nearly 4% Yield!
Sean Williams, The Motley Fool - Motley Fool - Sat May 10, 9:25AM CDT
Few industries offer investors as much long-term opportunity as the health-care sector. It's filled with tales of stocks doubling in a day on positive clinical data or the approval of a new medical device, as well as companies being chopped off at...
Theravance Study Results Confirm in vitro Potency of VIBATIV(R) (telavancin) and Efficacy in Patients With Complicated Skin and Skin Structure Infections Including MRSA
Marketwire - Fri May 09, 5:01PM CDT
Theravance, Inc. (NASDAQ: THRX) (the "Company"
European marketing authorisation granted for Anoro (umeclidinium/vilanterol) for the treatment of COPD
M2 - Fri May 09, 6:43AM CDT
Pharmaceutical companies GlaxoSmithKline plc (LSE/NYSE:GSK) and Theravance Inc (NASDAQ: THRX) announced on Thursday that marketing authorisation for Anoro (umeclidinium/vilanterol) as a once-daily, maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD) has been granted by the European Commission.
Anoro(R) (Umeclidinium/Vilanterol) Gains Marketing Authorisation in Europe for the Treatment of COPD
Marketwire - Thu May 08, 10:12AM CDT
GlaxoSmithKline plc (LSE: GSK) (NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the European Commission has granted marketing authorisation for Anoro(R) (umeclidinium/vilanterol) as a once-daily, maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
Split Update Overshadows Wider Q1 Loss at Theravance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 07, 10:40AM CDT
Theravance's (THRX) first quarter 2014 loss of 62 cents per share was wider than the Zacks Consensus Estimate of a loss of 53 cents per share.
Theravance, Inc. Announces May 15 Record Date and June 2 Share Issue Date for Separation Into Two Companies via a Stock Dividend
Marketwire - Wed May 07, 5:18AM CDT
Theravance, Inc. (NASDAQ: THRX) (the "Company" or "Theravance"
Theravance Unveils Separation Plans and Initiates Dividend As Q1 Loss Widens 81%
Sean Williams, The Motley Fool - Motley Fool - Tue May 06, 6:16PM CDT
Things are about to getting very exciting for existing shareholders of biopharmaceutical company Theravance , with the company announcing its first-quarter results after the closing bell and setting a record date of May 15 for its split into two...
Will These 3 Biotechs Bounce Back?
Dan Carroll, The Motley Fool - Motley Fool - Tue May 06, 5:30PM CDT
The biotech sector has been hit hard in 2014, with many of the biggest names in the industry taking falls. Three top companies, Alnylam Pharmaceuticals , Theravance , and Amgen , are all down year to date. But are these tumbling biotech stocks...
Downtrend Call Working As Theravance Stock Falls 22.0% (THRX)
Comtex SmarTrend(R) - Tue May 06, 9:24AM CDT
SmarTrend identified a Downtrend for Theravance (NASDAQ:THRX) on March 7th, 2014 at $34.65. In approximately 2 months, Theravance has returned 21.96% as of today's recent price of $27.04.
This Week in Biotech: Merger Mania Continues
Sean Williams, The Motley Fool - Motley Fool - Sat May 03, 12:15PM CDT
With the SPDR S&P Biotech Index up 23% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
Theravance to Present New Data Confirming in vitro Potency of VIBATIV(R) (telavancin) and Efficacy in Patients With Complicated Skin and Skin Structure Infections Including MRSA at 2014 ECCMID Conference
Marketwire - Thu May 01, 7:04AM CDT
Theravance, Inc. (NASDAQ: THRX) (the "Company"
Product Launches, Conference Call Schedules, Promotions, and Appointments - Analyst Notes on Theravance, Volcano, Steris, Cyberonics and Kythera
PR Newswire - Thu May 01, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Theravance Inc. (NASDAQ: THRX), Volcano Corporation (NASDAQ: VOLC), Steris Corp. (NYSE: STE), Cyberonics Inc. (NASDAQ: CYBX) and Kythera Biopharmaceuticals, Inc. (NASDAQ: KYTH). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1881-100free.
Theravance Announces Positive Results From a Phase 2 Study of TD-9855 in Patients With Fibromyalgia
Marketwire - Wed Apr 30, 3:09PM CDT
Theravance, Inc. (NASDAQ: THRX) today announced positive results from a Phase 2 study of TD-9855, an investigational norepinephrine and serotonin reuptake inhibitor (NSRI), in patients with fibromyalgia (FM). The study demonstrated statistically significant and clinically meaningful improvements in the primary and secondary endpoints at the 20 mg dose of TD-9855 compared to placebo. The 5 mg dose did not meet statistical significance for the primary endpoint. Both doses were generally well tolerated.
Theravance to Present at the Bank of America Merrill Lynch 2014 Health Care Conference
Marketwire - Tue Apr 29, 3:06PM CDT
Theravance, Inc. (NASDAQ: THRX) announced today that Rick E Winningham, Theravance's Chief Executive Officer, is scheduled to present at the Bank of America Merrill Lynch 2014 Health Care Conference on Tuesday, May 13, 2014, at 10:00 a.m. PDT. The conference will be held from May 13-15, 2014 at the Encore at Wynn Las Vegas, Las Vegas, NV.
Could This Be the Next Health Care Acquisition Target?
Sean Williams, The Motley Fool - Motley Fool - Tue Apr 29, 11:05AM CDT
If you follow the health-care sector in any way, shape, or form, the pay week and a half has been nothing short of incredible. Merger and acquisition activity usually comes in spurts, and true megadeals are rare . But in recent days we have been...
GlaxoSmithKline & Theravance partnership unveils Anoro Ellipta in the US for the treatment of COPD
M2 - Tue Apr 29, 5:44AM CDT
Healthcare company GlaxoSmithKline (LSE:GSK)(NYSE:GSK) and Theravance (NasdaqGS:THRX) Monday jointly reported the launch of Anoro Ellipta for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in retail pharmacies in the US.
Theravance Down 23.6% Since SmarTrend Downtrend Call (THRX)
Comtex SmarTrend(R) - Mon Apr 28, 5:11PM CDT
SmarTrend identified a Downtrend for Theravance (NASDAQ:THRX) on March 7th, 2014 at $34.65. In approximately 2 months, Theravance has returned 23.58% as of today's recent price of $26.48.